Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1996-09-03
1999-05-11
MacMillan, Keith D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514315, 514318, 514646, A61K31/445;31/54;31/135
Patent
active
059028157
ABSTRACT:
This invention relates to a new method for treating or preventing brain damage caused by NMDA receptor hypofunction (NR/hypo), using drugs such as lisuride which stimulate (agonize) activity at the 5HT-2A class of serotonin receptors, but which do not cause hallucinations. Data disclosed herein indicate that stimulation of both 5HT-2A and 5HT-2C receptors causes hallucinations, while stimulation of 5HT-2A receptors but not 5HT-2C receptors does not. Accordingly, to be useful herein, non-hallucinatory 5HT-2A agonists should either (1) antagonize (suppress) activity at 5HT-2C receptors, or (2) have no significant effect on activity at 5HT-2C receptors. Selective non-hallucinatory 5HT-2A agonists can be used in either of two treatment methods disclosed herein.
One such treatment comprises administering a 5HT-2A receptor agonist as a "safener drug" which accompanies an NMDA antagonist drug that is being used for a therapeutic purpose.
Another method disclosed herein involves the use of a 5HT-2A agonist drug, by itself, to combat a naturally-occurring form of NMDA receptor hypofunction which occurs in people suffering from schizophrenia. Although 5HT-2A agonists would not be optimally effective in treating long-standing cases of chronic schizophrenia, where pathological changes in the brain have already reached maximal or severe levels, 5HT-2A agonists can be administered early in the illness, such as at the first signs of schizophrenic illness, and continuously thereafter to prevent the development or worsening of pathological brain dysfunction and the resulting psychosis.
REFERENCES:
patent: 5034400 (1991-07-01), Olney
patent: 5474990 (1995-12-01), Olney et al.
patent: 5605911 (1997-02-01), Olney et al.
patent: 5629307 (1997-05-01), Olney et al.
Caldwell, M.A. et al, "The dopamine agonists lisuride and piribedil protect against behavioural and histological changes following 4-vessel occlusion in the rat," Neuropsychobiology 34: 117-24 (1996).
Calne, D.B. "Initiating treatment for idiopathic parkinsonism" Neurology 44: S19-S22 (1994).
Carlsson, M.L. "The selective 5-HT2A receptor antagonist MDL 100,907 counteracts the psychomotor stimulation ensuing manipulations with manoaminergic glutamatergic or muscarinic neurotransmission in the mouse--implications for psychosis" Journal of Neural Transmission 100: 225-237 (1995).
Eblen, F. et al, "Effects of 7-nitroindazole, NG-nitro-L-arginine, and D-CPPene on harmaline-induced postural tremor, N-methyl-D-aspartate-induced seizures, and lisuride-induced rotations in rats with nigral 6-hydroxydopamine lesions," Eur J Pharmacol 299 : 1-3 (1996).
Fink, H. et al "Locomotor effects of lisuride: A consequence of dopaminergic and serotonergic actions" Psychoparmacology 85: 464-468 (1985).
Fiorella, D. et al, Role of 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs. II: Reassessment of LSD false positives. Psychoparmacology 121: 357-63 (1995) (abstract).
Glennon, R.A. "Do Classical Hallucinogens Act As 5-HT2 Agonists of Antagonists?" Neuropsychopharmacology 3: 509-517 (1990).
Heinz, A. et al, "Clinical aspects and follow-up of dopamine-induced psychoses in continuous dopaminergic therapy and their implications for the dopamine hypothesis of schizophrenic symptoms" Nervenarzt 66: 662-9 (1995) (abstract).
Heinz, A. et al, "Continuous subcutaneous lisuride infusion in OPCA" Journal of Neural Transmission 90: 145-150 (1992).
Hougaku, H. et al, "Therapeutic effect of lisuride maleate on post-stroke depression" Nippon Ronen Igakkai Zasshi 31: 52-9 (1994) (abstract).
Kehne, J.H. et al, "Preclinical Characterization of the Potential of the Putative Atypical Antipsychotic MDL 100,907 as a Potent 5-HT2A Antagonist with a Favorable CNS Saftey Profile" The Journal of Pharmacology and Experimental Therapuetics 277: 968-981 (1996).
Maurel-Remy, S. et al, "Blockade of phencyclidine-induced hyperlocomotion by clozapine and MDL 100,907 in rats reflects antagonism of 5-HT2A receptors" European Journal of Pharmacology 280: R9-R11 (1995).
Olney, J.W., et al, "NMDA antagonist neurotoxicity: Mechanism and prevention," Science 254: 1515-1518 (1991).
Olney, J.W., et al, "Glutamate receptor dysfunction and schizophrenia," Arch. Gen. Psychiatry 52: 998-1007 (1995).
Pulvirenti, L. et al, "Dopamine receptor agonists, partial agonists and psychostimulant addiction" Trends Pharmacol Sci 15: 374-9 (1994).
Robles, R.G. et al, "Natriuretic Effects of Dopamine Agonist Drugs in Models of Reduced Renal Mass" Journal of Cardiovascular Pharmacology 22 (Suppl. 2): S88-S92 (1993).
Rosenfeld, M.R. et al, "The Interaction of Lisuride, and Ergot derivative with Serotonergic and Dopaminergic Receptors in Rabbit Brain" The Journal of Pharmacology and Experimental Therapeutics 216: 526-531 (1980).
Schmidt, C.J. et al, "The role of 5-HT2A receptors in antipsychotic activity" Life Sciences 56: 2209-2222 (1995).
Stocchi, F. et al, "Apomorphine and Lisuride Infusion" Advances in Neurology 60: 653-655 (1993).
Varty, G.B. et al, "Reversal of a dizocilpine-induced disruption of prepulse inhibition of an acoustic startle response by the 5-HT2 receptor antagonist ketanser" European Journal of Pharmacology 287: 201-205 (1995).
Chemical Abstracts AN 1992:563764, Wachtel et al, 1992.
Farber Nuri B.
Olney John W.
Kelly Patrick D.
MacMillan Keith D.
Washington University
LandOfFree
Use of 5HT-2A serotonin agonists to prevent adverse effects of N does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of 5HT-2A serotonin agonists to prevent adverse effects of N, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of 5HT-2A serotonin agonists to prevent adverse effects of N will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-245807